|
Index of reports
> Cases with Sepsis ()
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Rituxan (Rituximab) where reactions include sepsis. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Rituxan side effects in female
Reported by a physician from United States on 2012-08-02
Patient: female, weighing 141.5 kg (311.3 pounds)
Reactions: Leukocytoclastic Vasculitis, Hypotension, Sepsis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Rituxan
Possible Rituxan side effects in
Reported by a health professional (non-physician/pharmacist) from Canada on 2012-07-17
Patient:
Reactions: Sepsis
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Doxorubicin HCL
Indication: B-Cell Lymphoma
Prednisone
Indication: B-Cell Lymphoma
Rituxan
Indication: B-Cell Lymphoma
Vincristine
Indication: B-Cell Lymphoma
Possible Rituxan side effects in male
Reported by a health professional (non-physician/pharmacist) from France on 2012-07-17
Patient: male
Reactions: Fungal Infection, Sepsis
Adverse event resulted in: death
Drug(s) suspected as cause:
Chlorambucil
Dosage: from day 20 to 29 of each 35 days cycle, cycle 1
Indication: Mantle Cell Lymphoma
Chlorambucil
Dosage: from day 20 to 29 of each 35 days cycle, cycle 2
Chlorambucil
Dosage: from day 20 to 29 of each 35 days cycle, cycle 3
Chlorambucil
Dosage: from day 20 to 29 of each 35 days cycle, cycle 4
Dexamethasone
Dosage: from day 1 to 4 of each 35 days cycle, cycle 1
Indication: Mantle Cell Lymphoma
Dexamethasone
Dosage: from day 1 to 4 of each 35 days cycle, cycle 3
Dexamethasone
Dosage: from day 1 to 4 of each 35 days cycle, cycle 2
Dexamethasone
Dosage: from day 1 to 4 of each 35 days cycle, cycle 4
Doxorubicin HCL
Dosage: as a continuous infusion from day 1 to 4 each cycle of 35 days, cycle 3
Doxorubicin HCL
Dosage: as a continuous infusion from day 1 to 4 each cycle of 35 days, cycle 1
Indication: Mantle Cell Lymphoma
Doxorubicin HCL
Dosage: as a continuous infusion from day 1 to 4 each cycle of 35 days, cycle 2
Doxorubicin HCL
Dosage: as a continuous infusion from day 1 to 4 each cycle of 35 days, cycle 4
Rituxan
Dosage: on day 1 (day 8 of cycle 1) each cycle of 35 days, cycle 2
Rituxan
Dosage: on day 1 (day 8 of cycle 1) each cycle of 35 days, cycle 3
Rituxan
Dosage: on day 1 (day 8 of cycle 1) each cycle of 35 days, cycle 1
Indication: Mantle Cell Lymphoma
Rituxan
Dosage: on day 1 (day 8 of cycle 1) each cycle of 35 days, cycle 4
Velcade
Dosage: on days 1, 4, 8 and 11 each cycle of 35 days, cycle 2
Velcade
Dosage: on days 1, 4, 8 and 11 each cycle of 35 days, cycle 4
Velcade
Dosage: on days 1, 4, 8 and 11 each cycle of 35 days, cycle 3
Indication: Mantle Cell Lymphoma
Velcade
Dosage: on days 1, 4, 8 and 11 each cycle of 35 days, cycle 1
Possible Rituxan side effects in
Reported by a consumer/non-health professional from Germany on 2012-06-21
Patient:
Reactions: Sepsis, Progressive Multifocal Leukoencephalopathy, Meningitis Tuberculous
Adverse event resulted in: death
Drug(s) suspected as cause:
Busulfan
Dosage: 12 mg/kg, unk
Indication: Product Used FOR Unknown Indication
Carboplatin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Cisplatin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Cyclophosphamide
Dosage: 2000 mg/m2, unk
Indication: Product Used FOR Unknown Indication
Doxorubicin Hydrochloride
Dosage: unk
Indication: Product Used FOR Unknown Indication
Etoposide
Dosage: unk
Indication: Product Used FOR Unknown Indication
Fludara
Dosage: 250 mg/m2, unk
Indication: Product Used FOR Unknown Indication
Ifosfamide
Dosage: unk
Indication: Product Used FOR Unknown Indication
Neupogen
Dosage: unk
Indication: Product Used FOR Unknown Indication
Prednisone TAB
Dosage: unk
Indication: Product Used FOR Unknown Indication
Rituxan
Dosage: unk
Indication: Product Used FOR Unknown Indication
Vincristine Sulfate
Dosage: unk
Indication: Product Used FOR Unknown Indication
Zevalin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Possible Rituxan side effects in
Reported by a consumer/non-health professional from Canada on 2012-06-13
Patient:
Reactions: Sepsis, Progressive Multifocal Leukoencephalopathy, Meningitis Tuberculous
Adverse event resulted in: death
Drug(s) suspected as cause:
Busulfan
Dosage: 12 mg/kg, qd
Indication: Product Used FOR Unknown Indication
Carboplatin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Cisplatin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Cyclophosphamide
Dosage: 2000 mg/m2, qd
Indication: Product Used FOR Unknown Indication
Doxorubicin Hydrochloride
Dosage: unk
Indication: Product Used FOR Unknown Indication
Etoposide
Dosage: unk
Indication: Product Used FOR Unknown Indication
Fludara
Dosage: 250 mg/m2, qd
Indication: Product Used FOR Unknown Indication
Ifosfamide
Dosage: unk
Indication: Product Used FOR Unknown Indication
Neupogen
Dosage: unk
Indication: Product Used FOR Unknown Indication
Prednisone TAB
Dosage: unk
Indication: Product Used FOR Unknown Indication
Rituxan
Dosage: unk
Indication: Product Used FOR Unknown Indication
Vincristine Sulfate
Dosage: unk
Indication: Product Used FOR Unknown Indication
Zevalin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Possible Rituxan side effects in 75 year old male
Reported by a physician from United States on 2012-05-17
Patient: 75 year old male
Reactions: Renal Failure, Respiratory Failure, Sepsis, Pulmonary Embolism
Adverse event resulted in: death
Drug(s) suspected as cause:
Rituxan
Indication: Rheumatoid Arthritis
Start date: 2012-03-13
Rituxan
Start date: 2012-04-06
Rituxan
Start date: 2012-03-27
Rituxan
Start date: 2012-04-13
Possible Rituxan side effects in male
Reported by a physician from Romania on 2012-05-10
Patient: male, weighing 55.0 kg (121.0 pounds)
Reactions: Sepsis, Febrile Neutropenia
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Fludarabine Phosphate
Indication: Mantle Cell Lymphoma
Rituxan
Indication: Mantle Cell Lymphoma
Start date: 2011-12-28
End date: 2012-04-24
Other drugs received by patient: Acidum Ursodeoxycholicum; Vitamin B6; Arginin; Acyclovir; Silibinin; Acid Folic; Cotrim; Allopurinol
Possible Rituxan side effects in female
Reported by a consumer/non-health professional from United States on 2012-01-27
Patient: female
Reactions: Pneumonia, Sepsis
Adverse event resulted in: death
Drug(s) suspected as cause:
Humira
Indication: Rheumatoid Arthritis
Remicade
Indication: Product Used FOR Unknown Indication
Rituxan
Indication: Product Used FOR Unknown Indication
Possible Rituxan side effects in male
Reported by a physician from United States on 2011-12-20
Patient: male, weighing 108.0 kg (237.6 pounds)
Reactions: Neutropenic Infection, Sepsis, Lymphopenia, Hypocalcaemia, Pancytopenia, Blood Sodium Abnormal, Blood Glucose Abnormal
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Cyclophosphamide
End date: 2010-08-15
Cyclophosphamide
Indication: Burkitt's Lymphoma Stage IV
Cyclophosphamide
Start date: 2010-05-14
Cytarabine
End date: 2010-08-15
Cytarabine
Indication: Burkitt's Lymphoma Stage IV
Cytarabine
Start date: 2010-05-14
Cytarabine
Doxorubicin HCL
End date: 2010-08-15
Doxorubicin HCL
Doxorubicin HCL
Doxorubicin HCL
Indication: Burkitt's Lymphoma Stage IV
Start date: 2010-05-14
Etoposide
End date: 2010-08-15
Etoposide
Etoposide
Indication: Burkitt's Lymphoma Stage IV
Etoposide
Start date: 2010-05-14
Filgrastim
Start date: 2010-05-14
Filgrastim
Indication: Burkitt's Lymphoma Stage IV
Filgrastim
End date: 2010-08-15
Filgrastim
Ifosfamide
Start date: 2010-05-14
Ifosfamide
End date: 2010-08-15
Ifosfamide
Ifosfamide
Indication: Burkitt's Lymphoma Stage IV
Leucovorin Calcium
Start date: 2010-05-14
Leucovorin Calcium
Leucovorin Calcium
Indication: Burkitt's Lymphoma Stage IV
End date: 2010-08-15
Leucovorin Calcium
Methotrexate
Indication: Burkitt's Lymphoma Stage IV
End date: 2010-08-15
Methotrexate
Methotrexate
Methotrexate
Start date: 2010-05-14
Rituxan
Indication: Burkitt's Lymphoma
Start date: 2010-05-14
Rituxan
End date: 2010-08-15
Rituxan
Rituxan
Vincristine
Vincristine
Vincristine
Indication: Burkitt's Lymphoma Stage IV
End date: 2010-08-15
Vincristine
Start date: 2010-05-14
|
